Table 5.
Durvalumab based combinational therapy.
| Cancer type | Treatment | Dose schedule | Efficacy | Adverse rate | Notes | References |
|---|---|---|---|---|---|---|
| NSCLC | Durvalumab + tremelimumab | D q4w × 13 doses + T q4w for 6 doses, followed by T q12w × 3 doses Escalation dose of D: 3, 10, 15, 20 mg/kg Escalation dose of T: 1, 3, 10 mg/kg |
17% ORR | 36% TRAEs |
NCT02000947 Patients with locally advanced or metastatic NSCLC, immunotherapy-naïve |
(Antonia et al., 2016) |
| Durvalumab + gefitinib | 10 mg/kg D q2w + 250 mg gefitinib q1d | ORR 77.8% | 100% TRAEs |
NCT02088112 Patients harboring sensitizing EGFR mutations associated with advanced NSCLC, TKI-naive |
(Gibbons et al., 2016) | |
| 250 mg gefitinib q1d for 4 weeks, followed by 10 mg/kg D q2w + 250 mg gefitinib q1d | ORR 80% | 100% TRAEs | ||||
| Women's cancers | Durvalumab + olaparib | 10 mg/kg D q2w or 1,500 mg D q4w + olaparib Escalation dose of olaparib: 200, 300 mg |
17% ORR | – |
NCT02484404 Patients with TNBC or ovarian cancer |
(Lee J.M. et al., 2017) |
| 10 mg/kg D q2w or 1,500 mg D q4w + cediranib Escalations dose of cediranib: 20, 30 mg |
50% ORR | – | ||||
| Lymphoma | Durvalumab + ibrutinib | 560 mg ibrutinib q1d + 10 mg/kg D q2w for 28-day cycles | 25% ORR | 20% TRAEs |
NCT02401048 Patients with relapsed/refractory DLBCL or FL |
(Herrera et al., 2020) |